Stock Ratings / Health Care / XRAY / earnings

LMAT (74) KMTS (43) INSP (61) ATEC (38) ⌘ Pro Terminal →

DENTSPLY SIRONA Inc. (XRAY) Next Earnings Date & Expected ±7.8% Move

$9.61 +1.80% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $9.62

DENTSPLY SIRONA Inc. (XRAY) carries a Roarable Rating of D (Sell) with 46/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (46/100 · D) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE D • SELL / AVOID Cap $1.92B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $9.62 (+0.13%)🧬 Disciplined Float (-0.40% YoY Shares)⚙️ Cash Engine: 5/20 (E) • 6.4% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (46/100 · D) historically underperformed SPY in 71% of rolling 90-day windows (-6.1% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERSELL / AVOID • D

2-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D · Rk D

Each axis scored 0–20

12M PRICE TARGET CONE-5.4% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for XRAY)Realized 20D OHLCV Swing Band: ±7.8%

Deterministic 5-Pillar Attribution (46/100 Composite)

🔍 WHY XRAY SCORES 46/100 (D) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Whale & Options Positioning+14/20 pts (30% of score)

20D Institutional Volume Accumulation (±7.8% realized swing band)

▲ #2 Bullish Driver: Macro Regime Fit+13/20 pts (28% of score)

FRED Regime × Technicals: 20% of 52W Range • RSI-14 at 55.1 (BULLISH MOMENTUM)

▼ #1 Drag / Risk Factor: SEC 10-K Forensic Risk5/20 pts (-15 pt drag)

Balance-sheet & 10-K footnote risk deducts 15 pts from forensic ceiling

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade E$8.83-2.9% Next Q

Q2 (-2Q)

Grade D$8.57+10% Next Q

Q3 (-1Q)

Grade D$9.43+1.9% Next Q

Current

Grade D$9.61-6.1% Hist 90D α

Trajectory: E (38) → D (46)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a XRAY Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While XRAY currently carries a cautious 46/100 (D) rating due to SEC 10-K Forensic Risk (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($9.70) and Max Pain ($10.09) forces dealer call-delta covering toward $15.50.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (-0.40% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $XRAY• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “XRAY Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 46%NO 54%Trade / Inspect Odds →

NEXT EST. WINDOW: Dec 30, 2026 (~58 DAYS)

Historical OHLCV Volatility ±7.8% Swing Band

±$0.75 Expected Swing

MODEL EARNINGS SETUP GAUGE

XRAY Quantitative Pre-Earnings Setup: 46/100

Trailing EPS: $4.25 • YoY Revenue Growth: -3%

Model Bullish Setup (46/100)Model Risk Weight (54/100)

Derived deterministically from RQD cash-flow quality, SEC accrual safety, and institutional flow (not a community poll).

LOG YOUR PERSONAL PRE-EARNINGS STANCE (SAVED LOCALLY IN BROWSER):

Recent SEC Reported Revenue, Net Profit & Diluted EPS Cadence

Period	Filed	Revenue	Net Profit	Free Cash Flow	Gross Margin
FY 2025	2025-12-31	$3.68B	-$598.0M	$235.0M	50%
FY 2024	2024-12-31	$3.79B	-$910.0M	$461.0M	51.6%
FY 2023	2023-12-31	$3.96B	-$132.0M	$377.0M	50%

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring XRAY)

✓Walkthrough of XRAY's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

XRAY // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -18.21%📐 HORIZONTAL RANGE

2026-10-30O $9.55H $9.68L $9.41C $9.61VOL 3.50M

RES: $11.64SUP: $8.20SMA50: $9.70SMA200: $11.33

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

XRAY Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 XRAY Butterfly Map → + Track XRAY →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. -3.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on XRAY today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for XRAY. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for XRAY today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (XRAY)

Health Care Rank #441 of 1016 ⚔️ LMAT vs XRAY Full Matrix →

1. Head-to-Head Health Care Peer Comparison (XRAY vs. LMAT, KMTS, INSP, ATEC)

Industry: Medical/Dental Instruments (120 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, DENTSPLY SIRONA Inc. (XRAY) ranks #441 by composite RQD confidence (46/100, grade D) and #269 by equity capitalization ($1.92B). Within this direct 5-issuer industry benchmark cohort, INSP leads on earnings valuation at 14.2x trailing P/E, while LMAT leads on capital efficiency and profitability with 14.7% ROIC and 71.5% gross margin. LMAT currently holds the highest overall quantitative score in the immediate peer group at 74/100 (B) compared with XRAY at 46/100 (D).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
XRAY ACTIVE DENTSPLY SIRONA Inc.	D	46/100	—	50.0%	-11.0%	+1.80%	$1.92B	Benchmark Subject
LMAT LeMaitre Vascular Inc.	B	74/100	33.8x	71.5%	14.7%	+2.90%	$1.95B	/lmat-vs-xray →
KMTS Kestra Medical Technologies Ltd.	D-	43/100	—	51.4%	-35.0%	+2.48%	$1.82B	/kmts-vs-xray →
INSP Inspire Medical Systems Inc.	C-	61/100	14.2x	85.4%	6.0%	+0.30%	$2.06B	/insp-vs-xray →
ATEC Alphatec Holdings Inc.	D-	38/100	—	69.6%	-18.4%	-0.70%	$1.76B	/atec-vs-xray →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0000818479

In its most recent audited fiscal period (FY2025, filed 2025-12-31), DENTSPLY SIRONA Inc. (XRAY) reported GAAP revenue of $3.68B (-3.0% vs. FY2024 revenue of $3.79B , and -7.2% cumulative change since FY2023) , GAAP net income of -$598.0M, operating cash flow of $235.0M, and free cash flow of $235.0M (-49.0% YoY). On the balance sheet, XRAY closed FY2025 with $5.43B in total assets against $2.02B in total debt (Altman Z-Score: 0.45, Piotroski F-Score: 6/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$3.68B	-$598.0M	$235.0M	$235.0M	$5.43B	$2.02B
FY2024 (FY)	2024-12-31	$3.79B	-$910.0M	$461.0M	$461.0M	$5.75B	$1.59B
FY2023 (FY)	2023-12-31	$3.96B	-$132.0M	$377.0M	$377.0M	—	—

3. XRAY Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is XRAY stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, DENTSPLY SIRONA Inc. (NASDAQ: XRAY) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 46/100 at a spot price of $9.61 (+1.80% 1D, market cap $1.92B). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 14/20, Executive Insider Alignment 5/20, FRED Macro Regime Fit 13/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, XRAY ranks #441 in composite RQD confidence.

How does XRAY compare to LMAT and KMTS in the Health Care sector?

Within the Health Care sector (Medical/Dental Instruments), XRAY carries a Roarable D (46/100 RQD), trailing P/E of N/A, gross margin of 50.0%, and ROIC of -11.0%. By comparison, LMAT (LeMaitre Vascular Inc.) holds a B grade (74/100 RQD, P/E 33.8x, ROIC 14.7%, cap $1.95B) and KMTS (Kestra Medical Technologies Ltd.) posts a D- grade (43/100 RQD, P/E N/A, ROIC -35.0%, cap $1.82B). Among the 5-stock peer group, INSP leads on earnings multiple (14.2x) while LMAT leads on capital efficiency (14.7% ROIC).

What are the biggest fundamental strengths and SEC risk factors for XRAY?

Per XRAY's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000818479), DENTSPLY SIRONA Inc. generated $3.68B in revenue (-3.0% YoY), -$598.0M in net income, and $235.0M in free cash flow against $5.43B in total assets and $2.02B in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is XRAY trading relative to its 50-day, 200-day, and 52-week technical levels?

XRAY last traded at $9.61 (+1.80% on volume of 3,552,540 shares), positioning the stock -0.93% below its 50-day simple moving average ($9.70) and -15.18% below its 200-day simple moving average ($11.33). Across its 52-week range of $8.32 to $14.76, XRAY sits at the 20.0% percentile with a 14-day RSI of 55.1 (BULLISH MOMENTUM) and an implied next-earnings move of ±7.8% ($8.86 to $10.36).

XRAY Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

When is XRAY's next earnings date?

Based on SEC filing cadence, DENTSPLY SIRONA Inc. (XRAY)'s next quarterly reporting window is estimated around Dec 30, 2026.

How much is XRAY stock expected to move on earnings?

Volatility modeling currently projects a ±7.8% event move for XRAY, spanning a range between $8.86 and $10.36.

Direct Sub-Reports: XRAY RQD Cockpit XRAY 12M Forecast XRAY Earnings & Move XRAY Dividends & DRIP XRAY Insiders & 13F XRAY Whale Options XRAY Profit Sankey XRAY News & Why